8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
Apr 3, 2026·SEC
Material company update
Mar 19, 2026·SEC
Skye Bioscience, Inc.(SKYE)Earnings, Financials & Key Ratios
SKYE•NASDAQ
Price updated Jun 19, 2026
AboutSkye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.Show more
- Revenue$0
- EBITDA-$57M-92.1%
- Net Income-$56M-110.5%
- EPS (Diluted)-1.41-93.2%
- ROE-126.85%-57.6%
SKYE Key Insights
Skye Bioscience, Inc. (SKYE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 1.4x book value
✗Weaknesses
- ✗Profits declining 53.5% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Weak momentum: RS Rating 20 (bottom 20%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when SKYE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SKYE Price & Volume
Skye Bioscience, Inc. (SKYE) stock price & volume — 10-year historical chart
Loading chart...
SKYE Growth Metrics
Skye Bioscience, Inc. (SKYE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-75.59%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-75.61%
Return on Capital
10 Years-652.22%
5 Years-758.77%
3 Years-781.81%
Last Year-131.39%
SKYE Recent Earnings
Skye Bioscience, Inc. (SKYE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (40%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.32-10.3%
$0.29
Rev
—
—
Q2 2026
Mar 10, 2026Metric
Actual
Est
EPS
$0.36-21.2%
$0.30
Rev
—
—
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.32+3.0%
$0.33
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.44-29.4%
$0.34
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.32vs $0.29-10.3% | — |
| Q2 2026 | Mar 10, 2026 | $0.36vs $0.30-21.2% | — |
| Q4 2025 | Nov 10, 2025 | $0.32vs $0.33+3.0% | — |
| Q3 2025 | Aug 7, 2025 | $0.44vs $0.34-29.4% | — |
Based on last 12 quarters of dataView full earnings history →
SKYE Peer Comparison
Skye Bioscience, Inc. (SKYE) competitors in Ophthalmology Therapies and Delivery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ATAI | 1.49B | 4.06 | -1.40 | 12.28% | -190.19% | -366.21% | 0.01 | |
 CMPS | 1.2B | 12.53 | -4.07 | -151.02% | ||||
 MNMD | 2.04B | 20.69 | -10.04 | -102.48% | ||||
 SNDL | 368.06M | 1.42 | -33.38 | 2.82% | -1.17% | -1% | 0.15 | |
 CRBP | 103.54M | 8.26 | -1.40 | -70.89% | 0.01 | |||
 YCBD | 7.56M | 0.72 | -0.66 | -1.5% | -13.29% | -33.59% | 107.70 | |
 NRXP | 68.62M | 3.97 | -2.96 | -10.7% | ||||
 JAZZ | 14.09B | 224.66 | -38.47 | 4.88% | 0.66% | 0.71% | 1.26 |
Compare SKYE vs Peers
Skye Bioscience, Inc. (SKYE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SKYE Income Statement
Skye Bioscience, Inc. (SKYE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 8.04K | 1.54K | 1.46K | 1.87K | 0 | 0 | 0 | 0 | 723.35K | 172.89K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -8.04K▲ 0% | -1.54K▲ 80.8% | -1.46K▲ 5.3% | -1.87K▼ 28.0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -723.35K▲ 0% | -172.89K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | 46.11% | 80.79% | 5.31% | -28.04% | 100% | - | - | - | - | - |
Operating Expenses | 3.86M | 4.69M | 6.63M | 6.29M | 7.85M | 18.31M | 34.74M | 30.19M | 57.44M | 58.91M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 3.55M | 4.36M | 4.39M | 4.34M | 4.92M | 6.09M | 7.85M | 17.73M | 15.8M | 15.98M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 311.3K | 329.97K | 2.24M | 1.94M | 2.93M | 6.01M | 5.82M | 18.7M | 42.36M | 42.93M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 2K | 0 | 0 | 6.21M | 21.06M | -6.23M | -723.35K | 0 |
Operating Income | -3.86M▲ 0% | -4.69M▼ 21.6% | -6.63M▼ 41.3% | -6.29M▲ 5.2% | -7.85M▼ 24.8% | -18.31M▼ 133.3% | -34.74M▼ 89.7% | -30.19M▲ 13.1% | -58.16M▼ 92.6% | -59.08M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | 13.69% | -21.61% | -41.34% | 5.19% | -24.78% | -133.34% | -89.69% | 13.08% | -92.64% | - |
EBITDA | -4.62M | -4.69M | -6.63M | -6.29M | -7.81M | -18.2M | -34.61M | -29.89M | -57.44M | -58.36M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | -3.63% | -1.59% | -41.35% | 5.19% | -24.28% | -132.89% | -90.2% | 13.63% | -92.15% | -65.08% |
D&A (Non-Cash Add-back) | -759K | 1.54K | 1.46K | 1.87K | 34.13K | 115K | 124.25K | 298.64K | 723.35K | 718.86K |
EBIT | -3.09M | -19.1M | 2.04M | -5.85M | -7.75M | -18.81M | -36.74M | -25.59M | -58.16M | -57.49M |
Net Interest Income | 0 | -94.68K | -1M | -706.36K | -767.51K | -644.76K | -806.3K | 2.3M | 1.88M | 974.6K |
Interest Income | 0 | 84 | 26 | 29 | 3 | 19.01K | 99.97K | 3.26M | 1.88M | 976.8K |
Interest Expense | 667 | 94.76K | 1M | 706.38K | 767.51K | 663.77K | 906.27K | 967.6K | 0 | 2.2K |
Other Income/Expense | 766.53K | -14.5M | 7.69M | -270K | -672.37K | -1.16M | -2.91M | 3.64M | 2.24M | 1.75M |
Pretax Income | -3.09M▲ 0% | -19.19M▼ 520.5% | 1.05M▲ 105.5% | -6.56M▼ 722.9% | -8.52M▼ 29.9% | -19.47M▼ 128.6% | -37.64M▼ 93.3% | -26.56M▲ 29.4% | -55.92M▼ 110.6% | -57.33M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | 1.6K | 1.64K | 1.6K | 1.6K | 2.1K | 6.74K | 3.6K | 10.07K | 5.4K | 3.4K |
Effective Tax Rate % | -0.05% | -0.01% | 0.15% | -0.02% | -0.02% | -0.03% | -0.01% | -0.04% | -0.01% | -0.01% |
Net Income | -3.09M▲ 0% | -19.19M▼ 520.4% | 1.05M▲ 105.5% | -6.56M▼ 723.7% | -8.52M▼ 29.9% | -19.48M▼ 128.6% | -37.64M▼ 93.2% | -26.57M▲ 29.4% | -55.92M▼ 110.5% | -57.33M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | 2.64% | -520.36% | 105.48% | -723.67% | -29.89% | -128.6% | -93.23% | 29.43% | -110.5% | -75.59% |
Net Income (Continuing) | -3.09M | -19.19M | 1.05M | -6.56M | -8.52M | -19.48M | -37.64M | -26.57M | -55.92M | -57.33M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -25.62▲ 0% | -36.51▼ 42.5% | 1.98▲ 105.4% | -7.46▼ 476.8% | -5.00▲ 33.0% | -8.77▼ 75.4% | -5.37▲ 38.8% | -0.73▲ 86.4% | -1.41▼ 93.2% | -1.44▲ 0% |
EPS Growth % | 35.79% | -42.51% | 105.42% | -476.77% | 32.98% | -75.4% | 38.77% | 86.41% | -93.15% | -75.61% |
EPS (Basic) | -25.62 | -36.51 | 1.98 | -7.11 | -5.00 | -8.77 | -5.37 | -0.73 | -1.41 | - |
Diluted Shares Outstanding | 120.77K | 525.78K | 532.01K | 925.68K | 1.63M | 2.22M | 7.01M | 36.49M | 39.66M | 39.68M |
Basic Shares Outstanding | 120.77K | 525.78K | 532.01K | 922.99K | 1.63M | 2.22M | 7.01M | 36.49M | 39.66M | 39.68M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SKYE Balance Sheet
Skye Bioscience, Inc. (SKYE) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 555.81K | 1.95M | 1.99M | 2.66M | 9.61M | 8.94M | 11.65M | 70.83M | 27.09M | 18.57M |
Cash & Short-Term Investments | 259.95K | 1.85M | 1.83M | 2.47M | 8.98M | 1.24M | 1.26M | 68.42M | 25.74M | 17.11M |
Cash Only | 259.95K | 1.85M | 1.83M | 2.47M | 8.98M | 1.24M | 1.26M | 68.42M | 5.88M | 8.15M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19.85M | 8.96M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 74.12K | 158.24K | 5.07K | 10.47K | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 4.43K | 7.12K | 12.09K | 4.84K | 61.44K | 6.74M | 9.64M | 207.21K | 1.35M | 1.46M |
Total Non-Current Assets | 1.41K | 3.44K | 1.98K | 7.34K | 242.99K | 167.35K | 289.57K | 1.94M | 1.22M | 849.77K |
Property, Plant & Equipment | 1.41K | 3.44K | 1.98K | 7.34K | 234.68K | 159.04K | 281.26K | 1.88M | 1.17M | 813.86K |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 8.31K | 8.31K | 8.31K | 53.91K | 53.91K | 35.91K |
Total Assets | 557.22K▲ 0% | 1.96M▲ 251.2% | 2M▲ 2.0% | 2.67M▲ 33.8% | 9.86M▲ 268.9% | 9.11M▼ 7.5% | 11.94M▲ 31.1% | 72.76M▲ 509.4% | 28.31M▼ 61.1% | 19.42M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | 72.32% | 251.23% | 2.02% | 33.8% | 268.87% | -7.55% | 31.05% | 509.39% | -61.09% | -220.66% |
Total Current Liabilities | 805.97K | 15.94M | 970.82K | 787.2K | 3.91M | 12.12M | 13.9M | 4.34M | 8.21M | 10.4M |
Accounts Payable | 100.92K | 15.6K | 139.81K | 381.37K | 900.01K | 1.79M | 956.75K | 569.25K | 2.03M | 3.94M |
Days Payables Outstanding | 4.58K | 3.69K | 34.9K | 74.36K | - | - | - | - | 1.03K | 6.34K |
Short-Term Debt | 235K | 0 | 0 | 64.06K | 1.97M | 1.9M | 4.37M | 0 | 189.65K | 60.98K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 271.71K | 15.74M | 410.6K | 38.57K | 435.57K | 7.48M | 969.62K | 549.15K | 5.98M | 6.41M |
Current Ratio | 0.69x | 0.12x | 2.05x | 3.38x | 2.46x | 0.74x | 0.84x | 16.32x | 3.30x | 1.78x |
Quick Ratio | 0.69x | 0.12x | 2.05x | 3.38x | 2.46x | 0.74x | 0.84x | 16.32x | 3.30x | 1.78x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 551.32K | 1.58M | 477.87K | 1.43M | 78.7K | 0 | 171.23K | 273.16K | 84K | 0 |
Long-Term Debt | 0 | 1.36M | 387.07K | 1.43M | 0 | 0 | 0 | 0 | 84K | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 78.7K | 0 | 171.23K | 273.16K | 0 | 172.49K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 551.32K | 219.45K | 90.8K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1.36M | 17.52M | 1.45M | 2.22M | 3.99M | 12.12M | 14.07M | 4.61M | 8.29M | 10.4M |
Total Debt | 235K | 1.36M | 387.07K | 1.5M | 2.14M | 1.98M | 4.62M | 455.59K | 273.65K | 60.98K |
Net Debt | -24.95K | -492.41K | -1.44M | -971.61K | -6.85M | 738K | 3.36M | -67.96M | -5.61M | -8.09M |
Debt / Equity | - | - | 0.71x | 3.32x | 0.36x | - | - | 0.01x | 0.01x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.14x |
Interest Coverage | -4635.68x | -201.53x | 2.04x | -8.29x | -10.10x | -28.34x | -40.54x | -26.45x | - | -26144.82x |
Total Equity | -800.08K▲ 0% | -15.56M▼ 1845.1% | 548.06K▲ 103.5% | 450.79K▼ 17.7% | 5.86M▲ 1200.9% | -3.01M▼ 151.3% | -2.13M▲ 29.1% | 68.15M▲ 3296.9% | 20.02M▼ 70.6% | 9.01M▲ 0% |
Equity Growth % | 44.86% | -1845.09% | 103.52% | -17.75% | 1200.88% | -151.3% | 29.13% | 3296.88% | -70.62% | -252.1% |
Book Value per Share | -6.63 | -29.60 | 1.03 | 0.49 | 3.61 | -1.35 | -0.30 | 1.87 | 0.50 | 0.23 |
Total Shareholders' Equity | -800.08K | -15.56M | 548.06K | 450.79K | 5.86M | -3.01M | -2.13M | 68.15M | 20.02M | 9.01M |
Common Stock | 33.62K | 133.91K | 182.9K | 288.07K | 476.11K | 3.65K | 12.35K | 30.98K | 33.38K | 35.13K |
Retained Earnings | -14.03M | -33.23M | -32.17M | -38.73M | -47.26M | -66.74M | -104.38M | -130.95M | -186.87M | -199.38M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SKYE Cash Flow Statement
Skye Bioscience, Inc. (SKYE) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -3.3M | -3.94M | -6.03M | -6.05M | -6.47M | -12.74M | -13.95M | -25.24M | -43.06M | -42.43M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | 7.17% | -19.55% | -52.88% | -0.43% | -6.95% | -96.82% | -9.48% | -80.89% | -70.63% | -125.03% |
Net Income | -3.09M | -19.19M | 1.05M | -6.56M | -8.52M | -19.48M | -37.64M | -26.57M | -55.92M | -57.33M |
Depreciation & Amortization | 8.04K | 1.54K | 1.46K | 1.87K | 34.13K | 115K | 124.25K | 298.64K | 723.35K | -176.48M |
Stock-Based Compensation | 608.68K | 674.96K | 680.46K | 302.74K | 869.21K | 629.03K | 987.51K | 8.32M | 7.77M | -2.19B |
Deferred Taxes | 0 | 0 | -8.69M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -496.78K | 14.47M | 629.29K | 107.76K | 497.01K | 6.76M | 23.05M | -4.66M | -360.75K | -8.71B |
Working Capital Changes | -323.85K | 100.19K | 295.71K | 94.19K | 646.94K | -761.9K | -469.31K | -2.63M | 4.73M | 7.47M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -173.73K | -85.32K | 134.21K | 241.56K | 518.64K | 799.74K | -701.28K | -586.53K | 1.4M | 2.08M |
Cash from Investing | -19.65K | -4.38K | 0 | -7.23K | -90.87K | 5.21M | 6.6M | -245.62K | -19.5M | 4.2M |
Capital Expenditures | -19.65K | -4.38K | 0 | -7.23K | -90.87K | -28.06K | -12.55K | -1.6M | -6.31K | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 5.31M | 0 | 0 | 0 | 270.98K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | -66.46K | 6.61M | 0 | 0 | 90.62K |
Cash from Financing | 3.51M | 5.54M | 6M | 6.7M | 13.08M | -208.79K | 16.44M | 83.56M | 29.57K | -41.95K |
Debt Issued (Net) | 500K | 2.35M | 5.2K | 566.7K | 0 | -210.76K | 4.71M | 0 | 0 | -71.53K |
Equity Issued (Net) | 3.01M | 3.1M | 1.92M | 6.09M | 6.06M | 1.97K | 11.73M | 83.56M | 29.57K | 29.57K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 98.7K | 4.08M | 48.53K | 7.02M | 0 | -6.03K | 5.62K | 0 | 0 |
Net Change in Cash | 195.13K▲ 0% | 1.59M▲ 716.6% | -23.37K▼ 101.5% | 639.46K▲ 2836.2% | 6.51M▲ 918.6% | -7.74M▼ 218.8% | 9.09M▲ 217.4% | 58.08M▲ 539.1% | -62.53M▼ 207.7% | -38.27M▲ 0% |
Free Cash Flow | -3.32M▲ 0% | -3.95M▼ 19.0% | -6.03M▼ 52.7% | -6.06M▼ 0.6% | -6.57M▼ 8.3% | -12.77M▼ 94.5% | -13.96M▼ 9.3% | -26.84M▼ 92.2% | -43.07M▼ 60.5% | -42.43M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | 6.91% | -18.97% | -52.71% | -0.55% | -8.32% | -94.53% | -9.34% | -92.21% | -60.46% | 99.54% |
FCF per Share | -27.47 | -7.51 | -11.33 | -6.55 | -4.04 | -5.75 | -1.99 | -0.74 | -1.09 | -1.07 |
FCF Conversion (FCF/Net Income) | 1.07x | 0.21x | -5.73x | 0.92x | 0.76x | 0.65x | 0.37x | 0.95x | 0.77x | 0.74x |
Interest Paid | 0 | 23.33K | 371.42K | 117.46K | 44.09K | 333.55K | 198.35K | 433.34K | 0 | 0 |
Taxes Paid | 1.63K | 1.64K | 1.6K | 1.6K | 1.6K | 6.74K | 3.6K | 5.2K | 0 | 0 |
SKYE Key Ratios
Skye Bioscience, Inc. (SKYE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | 191.95% | -1313.72% | -269.9% | -1364.2% | - | -80.48% | -126.85% | -217.27% |
Return on Invested Capital (ROIC) | - | - | - | - | - | - | -2123.19% | -3192.59% | -597.29% | -352.62% |
Debt / Equity | - | - | 0.71x | 3.32x | 0.36x | - | - | 0.01x | 0.01x | 0.01x |
Interest Coverage | -4635.68x | -201.53x | 2.04x | -8.29x | -10.10x | -28.34x | -40.54x | -26.45x | - | -26144.82x |
FCF Conversion | 1.07x | 0.21x | -5.73x | 0.92x | 0.76x | 0.65x | 0.37x | 0.95x | 0.77x | 0.74x |
Related:SKYE Dividend History·SKYE Revenue History·SKYE Price History·SKYE P/E History·SKYE Financial Ratios·SKYE Institutional Holders
SKYE SEC Filings & Documents
Skye Bioscience, Inc. (SKYE) SEC filings — annual & quarterly reports (10-K, 10-Q)
SKYE Frequently Asked Questions
Skye Bioscience, Inc. (SKYE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Skye Bioscience, Inc. (SKYE) grew revenue by 0.0% over the past year. Growth has been modest.
Skye Bioscience, Inc. (SKYE) reported a net loss of $57.3M for fiscal year 2025.
Dividend & Returns
Skye Bioscience, Inc. (SKYE) has a return on equity (ROE) of -126.8%. Negative ROE indicates the company is unprofitable.
Skye Bioscience, Inc. (SKYE) had negative free cash flow of $42.4M in fiscal year 2025, likely due to heavy capital investments.